
PhII Alzheimer's data looming, Shionogi spending up to $500M on a buyout involving one of the toughest bets in biotech
Shionogi moved a couple of months ago to get in tight with a low-profile biotech called Tetra Therapeutics in Grand Rapids, MI. And whatever they learned about their 2 Phase II studies in Alzheimer’s and Fragile X syndrome persuaded the pharma player to ante up to $500 million more on a buyout.
Tuesday morning, Shionogi announced that it is buying Tetra outright as the biotech navigates the final stretches on 2 mid-stage trials.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.